Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign up Log in
All Resources Treatments A-Z Personal Assistant What is This Site Help Center Crisis
Powered By

Top 4 search results for "Lunsumio" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
Follicular Lymphoma Stages and Grades: What To Expect With Progression
... Burst Edition: FDA Approval of Lunsumio (Mosunetuzumab-Axgb) for Adult Patients With Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy — U.S. Food and Drug Administration Oncology (Cancer)/Hematologic Malignancies Approval Notifications — U.S. ...
Follicular Lymphoma Stages and Grades: What To Expect With Progression
... Burst Edition: FDA Approval of Lunsumio (Mosunetuzumab-Axgb) for Adult Patients With Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy — U.S. Food and Drug Administration Oncology (Cancer)/Hematologic Malignancies Approval Notifications — U.S. ...
What Is Follicular Lymphoma? Symptoms, Causes, and More
... — Journal of Oncology Practice In Bispecific Rivalry, AbbVie’s Epkinly Follows Roche’s Lunsumio Into Follicular Lymphoma — Fierce Pharma CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia — Clinical Advances in Hematology and Oncology FDA Grants Accelerated Approval to Lisocabtagene ...
What Is Follicular Lymphoma? Symptoms, Causes, and More
... — Journal of Oncology Practice In Bispecific Rivalry, AbbVie’s Epkinly Follows Roche’s Lunsumio Into Follicular Lymphoma — Fierce Pharma CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia — Clinical Advances in Hematology and Oncology FDA Grants Accelerated Approval to Lisocabtagene ...
Immunotherapy for Lymphoma: 4 Points To Know
... FDA-approved examples include: Epcoritamab-bysp (Epkinly) — For relapsed or refractory DLBCL or some B-cell lymphomas, and for use in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma Glofitamab-gxbm (Columvi) — For some relapsed or refractory large B-cell lymphomas Mosunetuzumab-axgb (Lunsumio) — For relapsed ...
Immunotherapy for Lymphoma: 4 Points To Know
... FDA-approved examples include: Epcoritamab-bysp (Epkinly) — For relapsed or refractory DLBCL or some B-cell lymphomas, and for use in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma Glofitamab-gxbm (Columvi) — For some relapsed or refractory large B-cell lymphomas Mosunetuzumab-axgb (Lunsumio) — For relapsed ...
8 Lymphoma Treatment Options: Chemo and Beyond
... Examples include drugs that target: CD20 — Obinutuzumab (Gazyva), ofatumumab, and rituximab Bispecific T-cell engagers — Epcoritamab-bysp (Epkinly), glofitamab-gxmb (Columvi), and mosunetuzumab-axgb (Lunsumio) CD19 on B lymphocytes — Tafasitamab-cxix (Monjuvi) Monoclonal antibodies that target antigens on cancer cells can also be combined with chemotherapy ...
8 Lymphoma Treatment Options: Chemo and Beyond
... Examples include drugs that target: CD20 — Obinutuzumab (Gazyva), ofatumumab, and rituximab Bispecific T-cell engagers — Epcoritamab-bysp (Epkinly), glofitamab-gxmb (Columvi), and mosunetuzumab-axgb (Lunsumio) CD19 on B lymphocytes — Tafasitamab-cxix (Monjuvi) Monoclonal antibodies that target antigens on cancer cells can also be combined with chemotherapy ...